How will yervoy's patent expiration impact sales?

How long will Yervoy keep its market exclusivity?

Yervoy's primary patent protection for melanoma use expired in 2024. Secondary patents covering combination use with Opdivo still protect that regimen until at least 2034. The earliest possible generic entry is therefore 2034 unless a court invalidates those later patents.

Why are companies challenging this patent?

No companies have filed Paragraph IV challenges against the remaining Opdivo-Yervoy combination patents. Current litigation focuses on the 2034 patents covering ipilimumab plus nivolumab in renal cell carcinoma and other solid tumors. Companies would gain entry rights if any of those patents were ruled invalid or not infringed.

How does Yervoy sales performance compare with Opdivo sales?

Yervoy sales reached $2.4 billion in 2023, roughly 15 percent of Bristol-Myers Squibb's oncology portfolio. Opdivo sales alone exceeded $9 billion. The combination regimen now accounts for nearly 70 percent of Yervoy's total revenue, so any early loss of combination protection would cut sales sharply.

Can biosimilars enter before patent expiry?

Yervoy is a biologic, so generic competition will take the form of biosimilars. Biosimilars of ipilimumab will require full FDA approval and interchangeability designations. No biosimilar applications have been accepted for review yet, but several companies have ipilimumab biosimilars in early development.

What will happen to pricing and reimbursement once generics arrive?

Current average wholesale price exceeds $18,000 per dose. Once biosimilars launch, payers are expected to prefer lower-cost versions. The 2024 Medicare negotiation round already lists ipilimumab under consideration, so price cuts of 40-50 percent are anticipated regardless of patent status.

When does Yervoy's patent expire?